ABBOTT LABORATORIES (ABT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-03-31..
Quick ratio
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 18.38B USD | Liabilities, Current |
| Cash and equivalents | 6.80B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 8.21B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 6.99B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $18.38B | $6.80B | (m) | $8.21B | $6.99B | (m) |
| 2025-12-31 | (m) | $16.50B | $8.52B | (m) | $7.93B | $6.49B | (m) |
| 2025-09-30 | (m) | $14.58B | $7.51B | (m) | $8.14B | $6.71B | (m) |
| 2025-06-30 | (m) | $13.44B | $6.95B | (m) | $7.97B | $6.95B | (m) |
| 2025-03-31 | (m) | $13.00B | $6.53B | (m) | $7.33B | $6.64B | (m) |
| 2024-12-31 | (m) | $14.16B | $7.62B | (m) | $6.92B | $6.19B | (m) |
| 2024-09-30 | (m) | $14.90B | $7.56B | (m) | $7.05B | $6.81B | (m) |
| 2024-06-30 | (m) | $13.76B | $6.99B | (m) | $6.85B | $6.81B | (m) |
| 2024-03-31 | (m) | $14.02B | $6.28B | (m) | $6.61B | $6.83B | (m) |
| 2023-12-31 | (m) | $13.84B | $6.90B | (m) | $6.57B | $6.57B | (m) |
| 2023-09-30 | (m) | $13.04B | $6.71B | (m) | $6.50B | $6.65B | (m) |
| 2023-06-30 | (m) | $14.35B | $7.83B | (m) | $6.17B | $6.87B | (m) |
| 2023-03-31 | (m) | $14.53B | $9.16B | (m) | $6.02B | $6.67B | (m) |
| 2022-12-31 | (m) | $15.49B | $9.88B | (m) | $6.22B | $6.17B | (m) |
| 2022-09-30 | (m) | $13.37B | $9.59B | (m) | $6.41B | $5.73B | (m) |
| 2022-06-30 | (m) | $12.39B | $8.94B | (m) | $7.20B | $5.90B | (m) |
| 2022-03-31 | (m) | $12.65B | $7.67B | (m) | $7.18B | $5.69B | (m) |
| 2021-12-31 | (m) | $13.11B | $9.80B | (m) | $6.49B | $5.16B | (m) |
| 2021-09-30 | (m) | $12.87B | $9.30B | (m) | $6.41B | $5.26B | (m) |
| 2021-06-30 | (m) | $12.61B | $8.66B | (m) | $6.11B | $5.44B | (m) |
| 2021-03-31 | (m) | $12.46B | $8.05B | (m) | $6.10B | $5.39B | (m) |
| 2020-12-31 | (m) | $11.91B | $6.84B | (m) | $6.41B | $5.01B | (m) |
| 2020-09-30 | (m) | $10.26B | $4.48B | (m) | $5.65B | $5.15B | (m) |
| 2020-06-30 | (m) | $10.96B | $4.76B | (m) | $5.14B | $5.20B | (m) |
| 2020-03-31 | (m) | $10.81B | $3.38B | (m) | $5.29B | $4.57B | (m) |
| 2019-12-31 | (m) | $10.86B | $3.86B | (m) | $5.42B | $4.32B | (m) |
| 2019-09-30 | (m) | $10.49B | $4.09B | (m) | $5.45B | $4.39B | (m) |
| 2019-06-30 | (m) | $9.06B | $3.14B | (m) | $5.55B | $4.35B | (m) |
| 2019-03-31 | (m) | $9.11B | $3.02B | (m) | $5.34B | $4.08B | (m) |
| 2018-12-31 | (m) | $9.01B | $3.84B | (m) | $5.18B | $3.80B | (m) |
| 2018-09-30 | (m) | $12.78B | $7.37B | (m) | $5.27B | $3.78B | (m) |
| 2018-06-30 | (m) | $8.95B | $3.06B | (m) | $5.19B | $3.71B | (m) |
| 2018-03-31 | (m) | $9.01B | $3.86B | (m) | $5.36B | $3.83B | (m) |
| 2017-12-31 | (m) | $8.91B | $9.41B | (m) | $5.25B | $3.60B | (m) |
| 2017-09-30 | (m) | $7.93B | $11.01B | (m) | $4.80B | $3.48B | (m) |
| 2017-06-30 | (m) | $6.80B | $9.68B | (m) | $4.63B | $3.60B | (m) |
| 2017-03-31 | (m) | $6.65B | $8.71B | (m) | $4.51B | $4.00B | (m) |
| 2016-12-31 | (m) | $6.66B | $18.62B | (m) | $3.25B | $2.43B | (m) |
| 2016-09-30 | (m) | $8.32B | $2.50B | (m) | $3.32B | $2.61B | (m) |
| 2016-06-30 | (m) | $8.67B | $2.58B | (m) | $3.57B | $2.81B | (m) |
| 2016-03-31 | (m) | $8.39B | $3.33B | (m) | $3.43B | $2.79B | (m) |
| 2015-12-31 | (m) | $9.19B | $5.00B | (m) | $3.42B | $2.60B | (m) |
| 2015-09-30 | (m) | $8.76B | $3.13B | (m) | $3.46B | $2.63B | (m) |
| 2015-06-30 | (m) | $9.19B | $4.05B | (m) | $3.55B | $2.73B | (m) |
| 2015-03-31 | (m) | $9.21B | $3.23B | (m) | $3.48B | $2.62B | (m) |
| 2014-12-31 | (m) | $10.53B | $4.06B | (m) | $3.59B | $2.64B | (m) |
| 2014-09-30 | (m) | $10.82B | $3.61B | (m) | $3.62B | $2.70B | (m) |
| 2014-06-30 | (m) | $9.85B | $3.57B | (m) | $4.06B | $2.82B | (m) |
| 2014-03-31 | (m) | $10.19B | $2.06B | (m) | $3.88B | $2.77B | (m) |
| 2013-12-31 | (m) | $9.51B | $3.48B | (m) | $3.99B | $2.69B | (m) |
| 2013-09-30 | (m) | $11.33B | $2.88B | (m) | $3.88B | $2.80B | (m) |
| 2013-06-30 | (m) | $10.92B | $5.57B | (m) | $3.94B | $2.73B | (m) |
| 2013-03-31 | (m) | $10.41B | $4.37B | (m) | $3.92B | $2.71B | (m) |
| 2012-12-31 | (m) | $13.28B | $10.80B | (m) | $7.61B | $3.79B | (m) |
| 2012-09-30 | (m) | $16.29B | $8.00B | (m) | $6.95B | $3.81B | (m) |
| 2012-06-30 | (m) | $17.12B | $7.05B | (m) | $6.77B | $3.52B | (m) |
| 2012-03-31 | (m) | $16.79B | $4.35B | (m) | $7.66B | $3.55B | (m) |
| 2011-12-31 | (m) | $15.48B | $6.81B | (m) | $7.68B | $3.28B | (m) |
| 2011-09-30 | (m) | $15.41B | $5.05B | (m) | $7.04B | $3.27B | (m) |
| 2011-06-30 | (m) | $15.84B | $4.08B | (m) | $7.04B | $3.48B | (m) |
| 2011-03-31 | (m) | $17.23B | $2.74B | (m) | $7.16B | $3.40B | (m) |
| 2010-12-31 | (m) | $17.26B | $3.65B | (m) | $7.18B | $3.19B | (m) |
| 2010-09-30 | (m) | $15.58B | $3.82B | (m) | $6.25B | $3.31B | (m) |
| 2010-06-30 | (m) | $14.69B | $4.32B | (m) | $6.34B | $3.17B | (m) |
| 2010-03-31 | (m) | $15.18B | $1.57B | (m) | $6.52B | $3.41B | (m) |
| 2009-12-31 | (m) | $13.05B | $8.81B | (m) | $6.54B | $3.26B | (m) |
| 2009-09-30 | (m) | $12.52B | $4.88B | (m) | $5.47B | $3.42B | (m) |
| 2009-06-30 | (m) | $12.04B | $4.20B | (m) | $5.45B | $3.52B | (m) |
| 2009-03-31 | (m) | (m) | $4.87B | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $11.59B | $4.11B | (m) | $5.47B | $2.78B | (m) |
| 2008-09-30 | (m) | (m) | $2.81B | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $3.80B | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $2.46B | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $521.19M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |